Last updated on December 2017

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Determine the Efficacy of Topical SGX301 (Synthetic Hypericin) and Fluorescent Bulb-Light Irradiation for the Treatment of Cutaneous T-Cell Lymphoma


Brief description of study

To evaluate the use of SGX301, a topical photosensitizing agent, to treat patients with patch/plaque phase cutaneous T-cell lymphoma (mycosis fungoides).

Other Details:
HPN-CTCL-01

Clinical Study Identifier: TX154820

Contact Investigators or Research Sites near you

Start Over

Magee McGriff

University of South Florida-Morsani College of Medicine
Tampa, FL USA
  Connect »